Dronabinol Treatment for Marijuana Addiction (MARINOL)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00217971
Recruitment Status :
First Posted : September 22, 2005
Results First Posted : November 1, 2011
Last Update Posted : April 24, 2019
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Frances R Levin, National Institute on Drug Abuse (NIDA)
All participants were seeking outpatient treatment for problems related to marijuana use and were recruited by local advertising or by clinical referrals in the New York City metropolitan area. Recruitment ran from 3/05-8/09 and patients participated in the trial at a research clinic at Columbia University.
The trial included a one-week placebo lead-in phase. Individuals who were able to significantly decrease their marijuana use during the first week of the study were not randomized. Participants who reported marijuana use less than twice a week during the placebo lead-in phase were considered placebo responders.
Dronabinol: 20mg bid for a daily ma...
Placebo:2 placebo capsules dosed bi...
Dronabinol: 20mg bid for a daily maximum dose of 40mg.
Placebo:2 placebo capsules dosed bid for a total of 4 capsules per day
Consequences of use are often long-term and more subtle. Thus, trying to initiate change over a relatively short period (i.e. patients in the present trial were maintained on the maximum dronabinol dose for only 6 weeks), may have been inadequate.